Skip to content
Trial Agents

European CRO activity evidence

CRO activity in European clinical trials: when outsourcing rises and which providers recur

European CRO use is not a fixed property of a phase or therapeutic area. Across Trial Agents cohorts, the clearest repeated signal is operational complexity: CRO support rises sharply as trials span more countries and sites, while the provider mix changes by disease and execution model.

The strongest recurring pattern is scale. In European oncology Phase III, CRO support rose from 5.9% of single-country trials to 90.4% of trials spanning at least 10 countries. Similar jumps appear in colorectal cancer, multiple sclerosis and IBD. At the same time, there is no universal CRO leader: IQVIA, ICON/PRA, PPD/Thermo Fisher, Parexel, Almac and specialist vendors recur in different combinations across cohorts.
CTIS timelinesEndpointsSites & investigatorsCRO activityAll reports
What the evidence shows

Recurring findings across European trials

1

Country footprint is one of the strongest recurring CRO-demand signals

In European oncology Phase III, CRO support rose from 5.9% of single-country trials to 32.4% at 2–4 countries, 67.5% at 5–9 countries and 90.4% at 10 or more countries. Colorectal cancer showed an even sharper split: only 9 of 121 single-country trials used CROs, while all 16 trials spanning 7 or more countries did. Multiple sclerosis reached 28 of 28 CRO-supported trials once the footprint reached 4 or more countries, and IBD reached 39 of 43 at 8 or more countries.

EvidenceWhich CROs Are Most Active in European Oncology Phase III Trials, and Where Is CRO Support Needed Most? · Which CROs Support Colorectal Cancer Phase II/III Trials in Europe, and When Are They Used Most? · Which CROs and Outsourced Functions Support European Multiple Sclerosis Phase II & III Trials? · Which CROs Are Most Active in European IBD Phase II and III Trials, and When Are They Needed Most?
2

Site-network scale produces the same pattern

Oncology Phase III CRO use increased from 10.9% in 1–5-site trials to 77.3% in trials with at least 50 sites. In IBD, 28 of 30 trials with 41 or more sites used CRO support, while heart-failure trials reached 13 of 18 once the network had 21 or more sites. The repeated signal is that distributed EU execution, not phase alone, is what most consistently drives external operational support.

EvidenceWhich CROs Are Most Active in European Oncology Phase III Trials, and Where Is CRO Support Needed Most? · Which CROs Are Most Active in European IBD Phase II and III Trials, and When Are They Needed Most? · Which CROs Are Most Active in European Heart Failure Phase II and Phase III Trials?
3

There is no universal CRO leader across therapeutic areas

IQVIA led the 887-trial European oncology Phase III cohort with 163 trial appearances and also led Phase III lung cancer with 39. ICON led colorectal cancer with 16 CRO-supported trials, while PPD/Thermo Fisher led renal cell carcinoma with 10. Ovarian cancer was jointly led by ICON/PRA and IQVIA at 15 CRO-supported trials each. Provider recurrence is therefore most useful when matched to the indication, phase and operational footprint of the planned study.

EvidenceWhich CROs Are Most Active in European Oncology Phase III Trials, and Where Is CRO Support Needed Most? · Which CROs support Phase III lung cancer trials in Europe from 2024 to 2026? · Which CROs Support Colorectal Cancer Phase II/III Trials in Europe, and When Are They Used Most? · Which CROs support European renal cell carcinoma phase 2 & 3 trials most often? · Which CROs Support Ovarian Cancer Phase II/III Trials in Europe, and When Are They Needed Most?
4

CRO selection is often a multi-vendor operating model, not a single-provider choice

IBD trials repeatedly listed full-service CROs alongside functional specialists: IQVIA appeared in 23 of 67 CRO-supported trials, ICON/PRA in 18, Labcorp in 17, Endpoint Clinical in 13, Clario/ERT in 12, and Almac, Medidata and PPD/Thermo Fisher in 11 each. Ovarian cancer showed the same pattern, with ICON/PRA and IQVIA leading overall while Clario/Bioclinica, Almac, PPD/Thermo Fisher and Medidata also recurred. One trial may list several providers, so the evidence supports separating full-service execution from imaging, lab, data, supply and other specialist functions.

EvidenceWhich CROs Are Most Active in European IBD Phase II and III Trials, and When Are They Needed Most? · Which CROs Support Ovarian Cancer Phase II/III Trials in Europe, and When Are They Needed Most?
5

Baseline outsourcing rates vary widely between comparable-looking cohorts

CRO support appeared in 67.9% of multiple-sclerosis Phase II/III trials, 67.0% of IBD trials, 62.7% of Phase III lung cancer, 59.3% of ovarian cancer, 55.6% of renal cell carcinoma and 51.1% of heart-failure trials. Colorectal cancer was 29.1% and CKD 27.8%. These are separate cohorts rather than a pooled benchmark, but the spread shows why a generic ‘CRO use in Europe’ percentage is not a useful planning target.

EvidenceWhich CROs and Outsourced Functions Support European Multiple Sclerosis Phase II & III Trials? · Which CROs Are Most Active in European IBD Phase II and III Trials, and When Are They Needed Most? · Which CROs support Phase III lung cancer trials in Europe from 2024 to 2026? · Which CROs Support Ovarian Cancer Phase II/III Trials in Europe, and When Are They Needed Most? · Which CROs support European renal cell carcinoma phase 2 & 3 trials most often? · Which CROs Are Most Active in European Heart Failure Phase II and Phase III Trials? · Which CROs Support Colorectal Cancer Phase II/III Trials in Europe, and When Are They Used Most? · Which CROs Are Most Active in European Phase II & III Chronic Kidney Disease Trials?
6

Phase alone is a weak outsourcing rule

Rheumatoid arthritis is a useful counterexample to a simple later-phase-equals-more-CRO assumption: CRO support appeared in 11 of 22 Phase II trials but only 1 of 8 Phase III trials. CKD similarly identified multi-country scope, larger site networks and sponsor/indication complexity as stronger signals than phase alone. The practical benchmark is the execution model of comparable trials, not the phase label in isolation.

EvidenceWhich CROs Are Most Active in European Rheumatoid Arthritis Phase 2 & 3 Trials? · Which CROs Are Most Active in European Phase II & III Chronic Kidney Disease Trials?

What this changes in trial planning

  • Benchmark CRO need against comparable country and site footprints before using phase or sample size as the main outsourcing proxy.
  • Use provider recurrence as evidence of experience in comparable trials, not as proof of quality or performance.
  • Separate full-service CRO selection from specialist functional needs such as imaging, central lab, eCOA, data and supply support.
  • Compare CROs within the closest therapeutic-area and execution cohorts rather than relying on a single Europe-wide leaderboard.

Scope note. This page synthesizes findings from separate Trial Agents analyses of European CTIS cohorts. Each statistic remains tied to the phase, disease, modality and time window of its underlying analysis. Cross-cohort patterns are used as planning signals, not pooled estimates or causal claims.

Underlying evidence

Read the analyses behind these findings

More evidence

Related European trial intelligence

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.